Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've ...
Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of Lilly ...
Investor's Business Daily on MSN17h
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking ZoneNovartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...
The biotech industry can be volatile even for relatively large companies. Amgen(NASDAQ: AMGN), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback